Medical Facilities Corporation

TSX:DR.TO

Medical - Care Facilities

Healthcare
$17.43 +1.01%

+$0.18 today

Market cap
$282.59M
Beta
0.34
P/E (TTM)
8.7
EPS (TTM)
$1.47
Dividend yield
2.00%
52W Low $13.59High $18.79

Volume 0.04M

Average 0.02M

DR.TO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Medical Facilities CorporationTSX: DR.TO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $14.54M (cash outflow) fell 74.8% year over year, behind the -43.9% change in trailing-twelve-month financing cash flow. Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Financing cash flow amounted to 41.5% of revenue in FY2025, up 16.1 pp from a year earlier.
  • Financing cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -74.8% toward the trailing-twelve-month pace of -43.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.54M-9.7% QoQ
Last fiscal yearDec 2025
-$107.3M+27.3% YoY
LTMMar 2026
-$67.77M-43.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.8%——
1 year+27.3%——
3-year CAGR+11.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(107.3M) USD
Year-over-year change
-27.3%

Financing Cash Flow vs competitors

How DR.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.9% is the 6th highest of 9, against a peer median of -9.1%.
  • Financing cash flow amounts to 22.2% of revenue for DR.TO, versus a peer median of 4.4%.
DR.TO Competitors
Financing Cash Flow for DR.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$399.12M CAD+168.5%—128.4%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.16M USD+399.3%+78.9%—
DR.TOMedical Facilities CorporationLTM Mar 2026$67.77M USD-43.9%+11.5%22.2%
PRN.TOProfound Medical Corp.LTM Mar 2026$42.16M USD+23.9%+81.2%224.7%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$25.62M USD+311.3%+6.4%50.1%
CRRX.TOCareRx CorporationLTM Mar 2026CA$16.16M CAD-42.1%+3.6%4.3%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$6.97M CAD-57.6%—4.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$2.03M CAD-101.9%—0.7%
TSND.TOTerrAscend Corp.LTM Mar 2026$601.11K USD-96.6%+4.6%0.2%
Peer median (excluding DR.TO) —-9.1%+6.4%4.4%

Competitors are the stored peer set for DR.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income46.49M12.3M44M105.56M21.08M
Depreciation & Amortization26.77M20.76M21.54M19.37M15.66M
Deferred Income Tax4.4M5.21M8.33M(3.67M)6.01M
Stock-Based Compensation292K(667K)(397K)(246K)0
Change in Working Capital(10.45M)(6.21M)(488K)(1.64M)(3.96M)
Accounts Receivables(1.23M)(2.6M)1.03M5.23M(4.02M)
Inventory659K1.42M(205K)(476K)(659.34K)
Accounts Payables(525K)2.46M(2.48M)(495K)1.86M
Other Working Capital(9.35M)(7.5M)1.17M(5.9M)(1.14M)
Other Non-Cash Items8.14M25.63M(183K)(36.09M)7.16M
Operating Cash Flow75.64M57.01M72.71M83.28M45.95M
Capital Expenditures(8.42M)(6.72M)(16.05M)(7.07M)(4.96M)
Acquisitions (Net)(267K)943K2.39M92.49M826.21K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(267K)943K2.39M00
Investing Cash Flow(8.69M)(5.78M)(13.67M)85.42M(4.14M)
Debt Repayment(30.05M)(6.47M)(28.84M)(32.82M)(2.62M)
Common Stock Issued00000
Common Stock Repurchased(2.07M)(38.38M)(7.42M)(16.61M)(64.78M)
Dividends Paid(6.92M)(7.5M)(6.07M)(6.1M)(5.18M)
Other Financing Activities(33.02M)(25M)(27.49M)(28.73M)(34.72M)
Financing Cash Flow(72.06M)(77.35M)(69.83M)(84.26M)(107.3M)
Effect of Forex Changes(34K)(3K)(34K)(59K)(4.77M)
Net Change in Cash(5.14M)(26.12M)(10.81M)84.38M(70.26M)
Free Cash Flow67.22M50.3M56.66M76.22M40.99M

Medical Facilities Corporation

TSX:DR.TO

Intrinsic Alpha fair value

Locked

Current Price

$17.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.